A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura

Kidney International

Volumn 75, Issue SUPPL. 112, 2009, Pages

  Foley, Stephen R ^a   Webert, Kathryn ^a   Arnold, Donald M ^b   Rock, Gail A ^c   Clark, William F ^d   Barth, David ^e   Sutton, David M ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Canadian Apheresis Group   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Anemia; Inhibitor; Monoclonal antibody; Rituximab; Thrombocytopenic

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FRESH FROZEN PLASMA; IMMUNOGLOBULIN G; PREDNISONE; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; VON WILLEBRAND FACTOR;

ADD ON THERAPY; ANTIBODY PRODUCING CELL; B LYMPHOCYTE; CANADA; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OPPORTUNISTIC INFECTION; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; BLOOD; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; REVIEW; RISK ASSESSMENT; TREATMENT FAILURE;

ADAM PROTEINS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; B-LYMPHOCYTES; CANADA; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT SELECTION; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; RISK ASSESSMENT; TREATMENT FAILURE; VON WILLEBRAND FACTOR;

EID: 63049092785     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.629     Document Type: Conference Paper

References (24)

1. George JN, el-Harak MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl Med 1994; 331: 1207-1211.
2. Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med 2006; 57: 419-436.
3. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-1935.
4. Furlan M, Robles R, Galbusera M et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremia syndrome. N Engl J Med 1998; 339: 1578-1584.
5. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl Med 1998; 22: 1585-1594.
6. Veyradier A, Obert B, Houllier A et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765-1772.
7. Mori Y, Wada H, Gabazza EC et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002; 42: 572-580.
8. Vesely SK, George JN, Lammle B et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-68.
9. Coppo P, Bengoufa D, Veyradier A et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004; 83: 233-244.
10. Zheng XL, Kaufman RM, Goudnough LT et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-4049.
11. Peyvandi F, Ferrari S, lavoretano S et al. von Willebrand factor cleaving protease (ADAMTS13) and ADAMTS13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004; 127: 433-439.
12. Coppo P, Wlf M, Veyradier A et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2006; 132: 66-74.
13. Tsai H-m, Li A, Rock G. Inhibitors of von Willebrand Factor cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab 2001; 47: 387-392.
14. Jin M, Casper TC, Cataland SR et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008; 141: 651-658.
15. Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl Med 1991; 325: 393.
16. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000; 96: 1223.
17. Rock GA. Management of thrombotic thrombocytopenic purpura. Br J Haematol 2000; 109: 496.
18. Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003; 14: 1072.
19. Allford SL, Hunt BJ, Rose P et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120: 556.
20. Sallah S, Husain A, Wan JY et al. Rituximab in patients with refractory thrombotic thrombocytopenic purpura. J Thromb Haemost 2004; 2: 834-836.
21. Ahmad A, Aggarwal A, Sharma D et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004; 77: 171-176.
22. Fakhouri F, Vernant JP, Veyradier A et al. Efficiency of curative and prophylactic treatment with Rituximab in ADAMTS13-sdeficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106: 1932-1937.
23. Scully M, Cohen H, Cavenagh J et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following Rituximab is associated with a reduction in IgG antibodies to ADAMTS13. Br J Haematol 2007; 136: 451-461.
24. Heidel F, Lipka DB, von Auer C et al. Addition of Rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 2007; 97: 228-233.